Aldesleukin Completed Phase 2 Trials for Melanoma, Experimental / Melanoma / Melanoma, Malignant Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00513604Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
NCT01266603High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
NCT00204581Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases
NCT01480323A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2